3Q EARNINGS: Will Actavis, CEO Saunders continue deal streak?

Actavis won't let its massive debt position – $15.1bn as of the third quarter of 2014 – get in the way of its dealmaking track record, including large transactions, which may or may not include the specialty biopharmaceutical company Allergan.